Trial Profile
A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary) ; Cannabinoids
- Indications Multiple sclerosis; Muscle spasticity
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
- 13 Nov 2020 Results from an analysis of three Phase 3 clinical trials of nabiximols(GWMS0106, GWSP0604, and SAVANT) published in the Greenwich Biosciences Media Release.
- 13 Nov 2020 According to a Greenwich Biosciences media release, data from an analysis of three Phase 3 clinical trials of nabiximols(GWMS0106, GWSP0604, and SAVANT) will be presented at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Virtual Annual Assembly. The research will be presented live during the November 14 Research Spotlight session on Neurological Rehabilitation.
- 01 May 2020 Results assessing the relationship between spasticity and muscle strength in lower extremities or mobility, using data from 3 RCTs (GWMS0106, GWSP0604, and SAVANT) presented at the 72nd Annual Meeting of the American Academy of Neurology